Navigation Links
FDA Clears OmniWave(TM) Endovascular System for Clot Removal in Peripheral Blood Vessels
Date:10/8/2007

WILMINGTON, Mass., Oct. 8 /PRNewswire/ -- OmniSonics Medical Technologies, Inc., a developer of advanced medical devices for use in the treatment of vascular disease, announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) to market its catheter based OmniWave(TM) Endovascular System for the infusion of physician specified fluids, including thrombolytics, and for the removal of thrombus in the peripheral vasculature.

The OmniWave Endovascular System is based on patented OmniWave(TM) Technology, the first minimally invasive catheter-based technology that delivers low-power, transverse ultrasonic energy to remove thrombus quickly, safely, and effectively. Thrombus (also known as a blood clot) occurs in a number of conditions including deep vein thrombosis (DVT), when large veins are blocked and acute limb ischemia, when there is a sudden decrease of blood flow to the arteries of a limb. DVT affects approximately 2 million people in the U.S. every year, and acute limb ischemia affects over 250,000 people in the U.S. every year.

"Clearly, this is a major accomplishment for the company as we continue on track towards building a world-class enterprise that can deliver advanced medical devices to treat vascular disease," said Richard Ganz, president and chief executive officer of OmniSonics. "The OmniWave System is designed to safely and rapidly remove blood clots in a single session. We believe that OmniWave Technology has the potential to be used in a wide range of vascular applications."

About OmniSonics Medical Technologies, Inc.

OmniSonics Medical Technologies, Inc., based in Wilmington, MA, is a venture-backed medical device company focused on developing breakthrough products for the treatment of vascular disease. The Company's products are based on its patented OmniWave(TM) Technology, the first technology capable of delivering low-power ultrasonic energy around the active length of a small diameter wire in a diseased blood vessel. OmniWave Technology is designed to have broad applications in vascular disease. See http://www.omnisonics.com .

Contact: Rhonda Rosenbaum

978-657-9980 X348

rrosenbaum@omnisonics.com


'/>"/>
SOURCE OmniSonics Medical Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. U.S. FDA Clears GE Healthcares New Bone Density System
2. New Mammalian Two-Hybrid System Detects Protein-Protein Interactions
3. Assess the In Vivo Activation of Signal Transduction Pathways with PathDetect Reporting Systems
4. Generate Adenovirus Vectors in E. coli by Homologous Recombination with the AdEasy Adenoviral Vector System
5. New Yeast Cloning System for Producing Proteins with Native Amino Acid Sequences
6. Enhanced PCR Cloning System
7. prostar RT-PCR Systems for Robust High-Fidelity RNA Amplification
8. Performance Comparisons of Commercial RT-PCR Systems
9. Signal Transduction Reporting Systems Using Cis-Acting Enhancer Elements
10. Yeast Protein Production System Features High Yields and One-Step Purification
11. Detect Released Oligosaccharides Using the Eagle Eye II Still Video Imaging System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... Pharmaceuticals, Inc. ("InMed") (CSE: IN; OTCQB: IMLFF), reported today that ... total of 10,672,750 common share purchase warrants have been exercised ... the exercise of these warrants totalled $1,387,458 and 10,672,750 common ... ... expression of confidence by our warrant holders. This infusion of ...
(Date:2/27/2017)... , Feb. 27, 2017 Fluxion Biosciences ... Spain has been appointed as a Certified ... The IsoFlux system will be used in Genetracer Biotech,s ... to lung and colon cancer, with plans to move ... laboratory is utilizing Fluxion,s IsoFlux System to isolate, recover, ...
(Date:2/25/2017)... (PRWEB) , ... February 25, 2017 , ... ... Verified Clinical Trials in an ongoing effort to create meaningful change ... advocacy, and pharmaceutical research with emphasis on consumers and patients’ mental health well-being. ...
(Date:2/24/2017)... 2017 Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, ... clinical-stage oncology and dermatology biopharmaceutical company, today is ... in its previously announced rights offering of up ... common stock and Series C Convertible Preferred Stock ... As previously announced, the rights ...
Breaking Biology Technology:
(Date:2/21/2017)... and PORTLAND, Ore. , Feb. ... the Avamere Family of Companies (Avamere Health Services, Infinity ... a six-month research study that will apply the power ... at senior living and health centers. By analyzing data ... to gain insights into physical and environmental conditions, and ...
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- RSA, ... that is designed to enhance fraud detection and ... in the RSA Fraud & Risk Intelligence Suite. ... to leverage additional insights from internal and external ... better protect their customers from targeted cybercrime attacks. ...
(Date:2/8/2017)... , Feb. 8, 2017 About Voice ... voice to match it against a stored voiceprint ... as pitch, cadence, and tone are compared to ... minimal hardware installation, as most PCs already have ... different transactions. Voice recognition biometrics are most likely ...
Breaking Biology News(10 mins):